Literature DB >> 25332246

Defining a role and predicting benefit from platinum-based therapy in breast cancer: an evolving story.

Joseph A Sparano1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25332246     DOI： 10.1200/JCO.2014.57.7890

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Wnt signaling in triple-negative breast cancer.

Authors:  Sö-G Pohl; N Brook; M Agostino; F Arfuso; A P Kumar; A Dharmarajan
Journal:  Oncogenesis       Date:  2017-04-03       Impact factor: 7.485

2.  Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy.

Authors:  Chunai Gong; Jing Tian; Zhuo Wang; Yuan Gao; Xin Wu; Xueying Ding; Lei Qiang; Guorui Li; Zhimin Han; Yongfang Yuan; Shen Gao
Journal:  J Nanobiotechnology       Date:  2019-09-03       Impact factor: 10.435

Review 3.  Role of Platinum in Early-Stage Triple-Negative Breast Cancer.

Authors:  Alyssa La Belle; Jude Khatib; William P Schiemann; Shaveta Vinayak
Journal:  Curr Treat Options Oncol       Date:  2017-11-06

4.  Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing.

Authors:  Nan Wang; Kun Li; Wenfa Huang; Weiyao Kong; Xiaoran Liu; Weijie Shi; Feng Xie; Hanfang Jiang; Guohong Song; Lijun Di; Quanren Wang; Jianjun Yu; Huiping Li
Journal:  Chin J Cancer Res       Date:  2020-04       Impact factor: 5.087
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.